Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6026 in HPV16/18-related HSIL
NCT07702656Phase 2Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jul 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SYS6026 in cervical squamous intraepithelial lesion (SIL) (4 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoint: Proportion of participants whose pathology had resolved/remission to CIN1 and HPV16/18 negative at 36 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
SYS6026
03
Conditions
cervical squamous intraepithelial lesion (SIL)
Beyond the preview
Go deeper on NCT07702656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07702656.